Mesalamine and other 5-ASA drugs: formulations, kidney checks and flare reporting

What 5-ASA drugs do and why formulation matters

Mesalamine, also called mesalazine, is the active 5-aminosalicylic acid that sulfasalazine releases in the colon, but without the sulfa carrier. It acts locally on the bowel lining to reduce inflammation and is mainly used to induce and maintain remission in mild to moderate ulcerative colitis.

Oral products use coatings or release systems so the drug is released in the small bowel or colon. Delayed-release and extended-release tablets and capsules are swallowed whole, not crushed or chewed, although some capsules may be opened following product instructions. Brands are not interchangeable, so a patient should stay on the prescribed product, and the nurse should query an unexplained switch.

On the exam, a mesalamine question often hinges on recognising that a delayed-release product depends on its coating. If a patient reports whole tablets in the stool, or the team proposes crushing a tablet for a feeding tube, the right response is to consult the pharmacist about a suitable alternative rather than improvise. Document the product name, not just the generic drug.

Rectal products and adherence in remission

Suppositories and enemas treat inflammation in the rectum and lower colon directly. Teach the patient to empty the bowel first if possible, lie on the left side for an enema, and retain it as long as instructed. Leakage or difficulty retaining the dose is worth reporting, because the prescriber may change the product rather than the drug.

Maintenance therapy is taken when the patient feels well, which is when adherence tends to slip. Explain that the goal is to keep remission, not just treat symptoms. Ask how many doses a week are missed and what gets in the way, such as pill burden or timing, rather than asking only whether they take it.

Kidney, blood and other adverse effects

Mesalamine can affect the kidneys, so kidney function tests are checked before and during treatment, and patients with kidney disease or kidney stones need closer review. Report reduced urine output, flank pain or rising creatinine. Blood tests also look for blood disorders, so unexplained bruising, bleeding, sore throat or fever need prompt reporting.

Common effects include headache, nausea, abdominal pain and diarrhoea. Less common serious effects include pancreatitis, liver injury, chest pain from heart inflammation and severe skin reactions. Ask about allergy to aspirin, salicylates or sulfasalazine before the first dose, and teach patients to limit prolonged sun exposure because photosensitivity can occur.

Acute intolerance or a disease flare

A rare acute intolerance reaction to mesalamine causes cramping abdominal pain, bloody diarrhoea, fever, headache and rash, which can look exactly like a colitis flare. The clue is timing: symptoms that start or worsen soon after starting the drug or increasing the dose deserve the question of whether the medicine itself is responsible.

Nurses do not decide which it is, but they gather the evidence: when the drug was started or changed, stool frequency and blood, temperature, pain and rash. Report this picture promptly rather than assuming a flare and encouraging extra doses. The prescriber decides whether to stop the drug, and stopping usually helps distinguish the two.

Worked scenario: worse diarrhoea after a dose increase

A hypothetical patient with ulcerative colitis had their mesalamine dose increased five days ago. They now report more bloody stools, cramping, a temperature of 38.4 C and a new rash. Options are to reassure them that the higher dose needs time, add an extra dose for the flare, or report possible intolerance.

Reporting possible acute intolerance is best. The timing after a dose change, plus fever and rash, makes a drug reaction a real possibility, and extra doses could worsen it. The time-to-work distractor is appealing because remission does take time, but new fever and rash are not expected effects. The prescriber reviews the drug and investigations.

Sources and further reading

MedlinePlus: Mesalamine. Formulations, swallowing whole, kidney disease, acute intolerance symptoms, salicylate and sulfasalazine allergy and sun sensitivity.

NHS: Mesalazine. Brands not interchangeable, forms including suppositories and enemas, kidney and blood tests and warning signs.

NHS: Side effects of mesalazine. Common effects, blood disorders, kidney stones, pancreatitis, chest pain, liver problems and skin reactions.